This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (CAI), Amphastar Pharmaceuticals (AMPH) and Amylyx Pharmaceuticals Inc (AMLX)

Tipranks - Tipranks - Sat May 9, 5:00AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Caris Life Sciences, Inc. (CAI), Amphastar Pharmaceuticals (AMPH) and Amylyx Pharmaceuticals Inc (AMLX).

Claim 55% Off TipRanks

Caris Life Sciences, Inc. (CAI)

Bank of America Securities analyst Michael Ryskin reiterated a Buy rating on Caris Life Sciences, Inc. yesterday and set a price target of $28.00. The company’s shares closed last Thursday at $19.84, close to its 52-week low of $16.28.

According to TipRanks.com, Ryskin is a 2-star analyst with an average return of 0.3% and a 48.2% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Tempus AI, Inc. Class A, and Fortrea Holdings Inc. ;'>

Currently, the analyst consensus on Caris Life Sciences, Inc. is a Strong Buy with an average price target of $29.92, implying a 56.4% upside from current levels. In a report released today, TD Cowen also maintained a Buy rating on the stock with a $31.00 price target.

See today’s best-performing stocks on TipRanks >>

Amphastar Pharmaceuticals (AMPH)

Bank of America Securities analyst Chi Meng Fong reiterated a Hold rating on Amphastar Pharmaceuticals yesterday and set a price target of $25.00. The company’s shares closed last Thursday at $24.03.

According to TipRanks.com, Fong is ranked #11254 out of 12242 analysts.

Currently, the analyst consensus on Amphastar Pharmaceuticals is a Moderate Buy with an average price target of $26.00, which is an 8.3% upside from current levels. In a report issued on April 22, TipRanks – xAI also reiterated a Hold rating on the stock with a $24.00 price target.

Amylyx Pharmaceuticals Inc (AMLX)

In a report released yesterday, Dina Ramadane from Bank of America Securities reiterated a Buy rating on Amylyx Pharmaceuticals Inc, with a price target of $22.00. The company’s shares closed last Thursday at $15.20.

According to TipRanks.com, Ramadane is a 2-star analyst with an average return of 1.8% and a 50.0% success rate. Ramadane covers the Healthcare sector, focusing on stocks such as Vera Therapeutics, Catalyst Pharma, and Biohaven Ltd. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amylyx Pharmaceuticals Inc with a $24.57 average price target, a 53.8% upside from current levels. In a report issued on May 5, TD Cowen also maintained a Buy rating on the stock.

Read More on CAI:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).